health
Two-trial analysis finds no clear mortality difference between cefazolin and penicillins for MSSA bacteremia
A medRxiv preprint pooling two randomized trials found no statistically significant difference in 90-day mortality between intravenous cefazolin and antistaphylococcal penicillins for adults with MSSA bacteremia. Estimates for kidney injury and treatment discontinuation favoured cefazolin in direction but were imprecise.